Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast (FACT-2)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03812393 |
Recruitment Status :
Recruiting
First Posted : January 23, 2019
Last Update Posted : October 12, 2020
|
Sponsor:
West Cancer Center
Collaborators:
Celcuity
Puma Biotechnology, Inc.
Information provided by (Responsible Party):
West Cancer Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | October 15, 2020 |
Estimated Study Completion Date : | April 15, 2023 |
Publications of Results: